Sprint Bioscience Q3 2022: Seal the deal

Research Update



Redeye comments on Sprint Bioscience’s Q3 2022 report, and we judge that the company is closing in on a licensing deal for its VADA project in late 2022e or H1 2023e. We preliminarily adjust our valuation for the company’s recently announced rights issue and increased cost control measures.



Christian Binder

Ethel Luvall

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.